Sanchitongshu

PreclinicalSmall molecule

XXinhua Hospital, Shanghai Jiao Tong University School of Medicine

Sanchitongshu is one of 41 small molecule programs targeting Transient Ischemic Attack. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Transient Ischemic AttackActive, not recruiting

Ischemic StrokeActive, not recruiting

Transient Ischemic AttackPreclinical

Active, not recruiting

Ischemic StrokePreclinical

Active, not recruiting

Competition

Competitive Landscape

430 competitors in Ischemic Stroke

#DrugCompanyPhaseTrials

Proamatine

Takeda

Preclinical

2 2

Repatha

Amgen

Preclinical

2 3

Tylenol

KKenvue Brands

Preclinical

1 4

Xylocaine

CCitius Pharmaceuticals, Inc.

Preclinical

1 5

Statins

Sanofi

Preclinical

1 6

Urokinase

Mmedac GmbH

Preclinical

3 7

Ginkgo Biloba Extract

NNational Center for Complementary and Integrative Health (NCCIH)

Preclinical

1 8

Actilyse

Boehringer Ingelheim

Preclinical

1 9

Aspirin or Clopidogrel

SSunnybrook Health Sciences Centre

Preclinical

1 10

Magnesium

SSpherium Biomed

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Ischemic stroke1 trial

Double Randomized and Placebo Controlled Trail of Sanchitongshu Combined Antiplatelet Drug to Prevent Ischemic Stroke

Unknown status·XXinhua Hospital, Shanghai Jiao Tong University School of Medicine·N/A·NCT04142151·60 enrolled

Transient Ischemic Attack1 trial

Sanchitongtshu Plus Asprine for Minor Ischemic Stroke or Transient Ischemic Attack: A Randomized Double-blind Study

Unknown status·XXinhua Hospital, Shanghai Jiao Tong University School of Medicine·N/A·NCT02975076·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Sanchitongshu. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Sanchitongshu compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Sanchitongshu. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Xinhua Hospital, Shanghai Jiao Tong University School of Medicine company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: XXinhua Hospital, Shanghai Jiao Tong University School of Medicine

Sanchitongshu

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Ischemic stroke1 trial

Transient Ischemic Attack1 trial

References

Drug Info

Quick Facts

Related News